BioCryst Pharmaceuticals Inc.
BioCryst develops rare‑disease therapeutics, selling peramivir for influenza and ORLADEYO for hereditary angioedema, while advancing phase‑1 BCX17725 for Netherton syndrome and other complement‑inhibitor candidates, supported by pharma and government collaborations.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Manufacturing
- Industry: Pharmaceutical Manufacturing
- Employees: 580
- HQ: Durham
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.